Mineralys Therapeutics, Inc. MLYS
Set alert
At close
Pre-market · Nov 2, 9:07 AM ET
- YTD
- -49.90%
- 1 year
- -55.51%
- Open
- 20.99
- Prev close
- 18.18
- Mkt cap
- 1.60B
- Vol
- 3.98M
- Avg vol
- 1.28M
- EPS
- -4.22
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 18.11
- High
- 20.99
- Forward P/E
- -7.40
- Beta
- 0.69
- Short ratio
- 4.98
- Inst. own
- 117.50%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 24.93
- 200-d avg
- 27.07
- 1y target
- 46.33
News
4 days ago globenewswire.com
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related…
-
5 days ago benzinga.com
Mineralys Therapeutics Announces Phase 2 Explore-CKD Trial Met Its Primary Endpoint; Publishes Full Results In The Journal 'Kidney International'
The Explore-CKD trial evaluated the efficacy and safety of lorundrostat, an aldosterone synthase inhibitor, added to guideline-directed background therapy in 59 participants with uncontrolled…
5 days ago globenewswire.com
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
- Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks -
-
3 weeks ago benzinga.com
UBS Initiates Coverage On Mineralys Therapeutics with Neutral Rating, Announces Price Target of $29
UBS analyst Alice Nettleton initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Neutral rating and announces Price Target of $29.
-
3 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $56 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and maintains $56 price target.
-
3 weeks ago benzinga.com
Mineralys Therapeutics Reports New Data Of Analysis From Its Pivotal Phase 3 Launch-HTN Study
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related outcomes in comorbid conditions such as chronic…
-
1 month ago benzinga.com
Mineralys Therapeutics To Present Five Abstracts At American Heart Association Hypertension Scientific Sessions 2026,
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as…
-
1 month ago benzinga.com
Mineralys Therapeutics To Present New Long-Term Efficacy And Safety Data From Ongoing Transform-HTN Open-Label Extension Trial Of Aldosterone Synthase Inhibitor Lorundrostat At AHA Scientific Sessions 2026
Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as…
4 months ago benzinga.com
7 Health Care Stocks With Whale Alerts In Today's Session
7 Health Care Stocks With Whale Alerts In Today's Session
-
4 months ago benzinga.com
Reported Sunday, Mineralys Therapeutics Presents Late-Breaking Data At ENDO 2026 Showing Lorundrostat Associated With Significant Reductions In Six Of Eleven Heart Failure Risk Biomarkers
– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –– Coordinated reductions…
-
4 months ago benzinga.com
Mineralys to Present New Trial Data at ENDO 2026, Proteomic Analysis Selected for Late-Breaking ENDO Poster
Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD),…
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
5 months ago benzinga.com
Mineralys Prices $150M Stock Offering Of 5.66M Shares At $26.50/Share, To Use Share Sale Proceeds for Royalty Buyback
Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD),…
5 months ago benzinga.com
AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios
AstraZeneca wins FDA approvals for Baxfendy in hypertension and Enhertu in early HER2-positive breast cancer treatment.
-
5 months ago benzinga.com
Mineralys Therapeutics Q1 EPS $(0.47), Inline
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.47) per share which met the analyst consensus estimate. This is a 40.51 percent increase over losses of $(0.79) per share from…
-
7 months ago benzinga.com
B of A Securities Maintains Buy on Mineralys Therapeutics, Raises Price Target to $51
B of A Securities analyst Greg Harrison maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $46 to $51.
-
7 months ago benzinga.com
Mineralys Therapeutics Q4 EPS $(0.40) Beats $(0.58) Estimate
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.58) by 30.68 percent. This is a 59.18 percent increase over losses…
-
7 months ago benzinga.com
Earnings Scheduled For March 12, 2026
Earnings Scheduled For March 12, 2026
-
7 months ago benzinga.com
Mineralys Therapeutics Says FDA Accepts NDA For Lorundrostat For Treatment Of Adult Patients With Hypertension In Combination With Other Antihypertensive Drugs; PDUFA Target Action Date December 22
– The FDA assigned a PDUFA target action date of December 22, 2026 –– The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction…
-
10 months ago benzinga.com
Stifel Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52
Stifel analyst Annabel Samimy maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $45 to $52.
-
10 months ago benzinga.com
Mineralys Therapeutics' Phase 3 Launch-HTN Trial Of Lorundrostat Featured In JAMA's Inaugural "Research Of The Year Roundup"
– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most…
-
11 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $56
HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $52 to $56.
-
11 months ago benzinga.com
Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $55
Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price target from $50 to $55.
-
11 months ago benzinga.com
Mineralys Therapeutics Q3 EPS $(0.52) Beats $(0.65) Estimate
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.65) by 19.38 percent. This is a 53.98 percent increase over losses…
11 months ago benzinga.com
Earnings Scheduled For November 10, 2025
Earnings Scheduled For November 10, 2025
-
11 months ago benzinga.com
Reported Friday, Mineralys Therapeutics Showcases Broad Clinical Potential of Lorundrostat Across Cardio-Renal-Metabolic Diseases
– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week –– Pivotal Phase 3 Launch-HTN trial featured in the "Best of JAMA and NEJM" session -
-
11 months ago benzinga.com
Uncovering Potential: Mineralys Therapeutics's Earnings Preview
Uncovering Potential: Mineralys Therapeutics's Earnings Preview
-
1 year ago benzinga.com
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52
HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $42 to $52.
-
1 year ago benzinga.com
Mineralys Therapeutics Presents Phase 2 Explore-CKD Trial Of Lorundrostat At ASN Kidney Week 2025
~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~~ Phase 3 data of the Launch-HTN…
-
1 year ago benzinga.com
Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $50
Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price target from $26 to $50.
-
1 year ago benzinga.com
Goldman Sachs Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52
Goldman Sachs analyst Richard Law maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $32 to $52.
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $42 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and maintains $42 price target.
-
1 year ago benzinga.com
Mineralys Therapeutics Presents Subgroup Data From Phase 3 Launch-HTN Trial At AHA 2025, Highlighting Lorundrostat's Efficacy In High-Risk Hypertension Populations
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~~Subgroups - including Black or…
1 year ago benzinga.com
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
Jefferies Maintains Hold on Mineralys Therapeutics, Raises Price Target to $26
Jefferies analyst Dennis Ding maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Hold and raises the price target from $15 to $26.
1 year ago benzinga.com
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
Mineralys Therapeutics Commences $175M Public Offering With $26.25M Over-Allotment Option
Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
1 year ago benzinga.com
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
1 year ago benzinga.com
Nasdaq Down 1%; Signet Jewelers Earnings Top Views
Nasdaq Down 1%; Signet Jewelers Earnings Top Views
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
1 year ago benzinga.com
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket
1 year ago benzinga.com
Nasdaq 100, S&P 500 Hit New All-Time Highs, Airlines Jump: What's Moving Markets Tuesday?
Wall Street is in full rally mode after July’s inflation data eased fears that tariff-related cost pressures were widespread. The headline Consumer Price Index (CPI) came in below expectations,…
-
1 year ago benzinga.com
Earnings Scheduled For August 12, 2025
Earnings Scheduled For August 12, 2025
1 year ago benzinga.com
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
1 year ago benzinga.com
Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher
Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher
1 year ago benzinga.com
Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket
Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
Earnings Scheduled For February 12, 2025
Earnings Scheduled For February 12, 2025